Systematic Review Links Mitochondrial Peptides to Metabolic Health

Mitochondrial Derived Peptides (MDPs) are small, bioactive peptides encoded by mitochondrial DNA, increasingly recognized for their crucial roles in regulating cellular metabolism, energy homeostasis, and stress responses. Dysregulation of these peptides has been implicated in the pathogenesis of various metabolic disorders such as obesity, insulin resistance, and type 2 diabetes. Despite growing individual studies, there has been a lack of a comprehensive synthesis to establish a clear and overall correlation between MDPs and diverse metabolic states.

The meta-analysis included a substantial body of evidence, encompassing 35 studies with a combined total of over 15,000 participants, revealing consistent and significant trends. The meta-analysis revealed a significant overall inverse correlation between circulating Mitochondrial Derived Peptides (MDPs) and the presence or severity of metabolic disorders. Specifically, levels of MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) were found to be significantly lower in individuals with type 2 diabetes compared to healthy controls (standardized mean difference (SMD) = -0.85, 95% CI: -1.02 to -0.68, p < 0.001). Furthermore, Humanin levels demonstrated a positive correlation with insulin sensitivity (pooled r = 0.42, p = 0.003) and were inversely associated with BMI (pooled r = -0.35, p = 0.008) across multiple cohorts. These findings collectively suggest that higher circulating MDP levels are generally associated with better metabolic health and reduced risk of metabolic dysfunction.